Xcout Intel
Guard Therapeutics Intl.
Guard Therapeutics International AB is a clinical-stage Swedish biotechnology company that researches and develops novel therapies targeting kidney diseases with significant medical needs. Its drug candidates are based on the endogenous protein alpha-1-microglobulin (such as the GTX peptides and RMC-035).
Subscribe to see Guard Therapeutics Intl.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Guard Therapeutics Intl. at a glance
Guard Therapeutics Intl. is a health care company headquartered in Sweden. Xcout tracks 6 named people at Guard Therapeutics Intl., including Johan Bygge (Styrelseordförande).
Guard Therapeutics Intl. leadership
- Johan ByggeStyrelseordförande
- Alexander Oker-BlomStyrelseledamot
- David BejkerStyrelseledamot
- Göran ForsbergStyrelseledamot
- Gunilla EkströmStyrelseledamot
- Tobias AgervaldStyrelseledamot
Guard Therapeutics Intl. competitors
A few of Guard Therapeutics Intl.'s closest competitors — see the full list of competitors and alternatives →
Diamyd Medical develops precision medicine therapies focused on the prevention and treatment of type 1 diabetes. The company's primary product is retogatein (rhGAD65), an investigational antigen-specific immunotherapy currently undergoing late-stage clinical trials.
Devicare, SL, founded in 2012 and headquartered in Barcelona, Spain, is a pharmaceutical company that specializes in health solutions for kidney and urinary tract health.
GutCRINE is a biotech spinout from the University of Copenhagen headquartered in Holte, Denmark, focused on developing new drugs to prevent and treat common diseases.
Salipro Biotech AB is a privately held biotechnology company headquartered in Stockholm, Sweden. The company is focused on unlocking challenging drug targets to advance drug discovery and develop next-generation therapeutics.
AlzeCure Pharma is a Swedish clinical-stage biopharmaceutical company developing small-molecule therapies for neurodegenerative diseases, particularly Alzheimer’s disease and related cognitive disorders. Its programs target disease mechanisms and symptoms, serving patients with serious central nervous system conditions through potential prescription medicines.
Breye Therapeutics ApS is a biotechnology company committed to closing the gap in eye care by developing first-in-class oral small molecule therapies to treat retinal diseases. The company is advancing oral therapies like danegaptide for the early treatment of these conditions.
Get Guard Therapeutics Intl.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Guard Therapeutics Intl.? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Guard Therapeutics Intl. in Xcout Intel
- 6 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access